This study by Claire Tonry et. al., is an awesome example of porting a biomarker discovery project directly into a clinical assay.
In this study they followed patientswho had treatments which pushed prostate cancer into remission. They followed the course after this and identified biomarkers from the unfortunate guys whose cancer recurred. Their comparison gave them 65 sweet new protein biomarkers that they were able to seemlessly convert into a beautiful new clinical assay for MRM. At 65 biomarkers, they could have used the discovery Q Exactive as the validation instrument (we're not seeing this enough yet!) but I'm certainly not going to complain.
This is a great study that shows how we can use these technologies complementarily (apparently..not a word...) to benefit patients.
No comments:
Post a Comment